The rapid uptake of immunotherapies has revolutionized cancer care for over a decade. However, response to immunotherapy varies substantially between patients, highlighting the importance of testing immuno-oncology (IO) treatments in diverse populations that reflect the heterogeneity of the oncology patient spectrum.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Competing Interests
The authors declare no competing interests.